Journal
NATURE CATALYSIS
Volume 2, Issue 9, Pages 780-792Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41929-019-0317-4
Keywords
-
Categories
Funding
- Molecular Structure Characterization Unit, RIKEN Center for Sustainable Resourse Science (CSRS)
- JSPS KAKENHI [JP16H03287, JP18K19154, JP18K14347, JP15H05843]
- Russian Government Program for Competitive Growth
Ask authors/readers for more resources
The ability of natural metalloproteins to prevent inactivation of their metal cofactors by biological metabolites, such as glutathione, is an area that has been largely ignored in the field of artificial metalloenzyme (ArM) development. Yet, for ArM research to transition into future therapeutic applications, biocompatibility remains a crucial component. The work presented here shows the creation of a human serum albumin-based ArM that can robustly protect the catalytic activity of a bound ruthenium metal, even in the presence of 20 mM glutathione under in vitro conditions. To exploit this biocompatibility, the concept of glycosylated artificial metalloenzymes (GArM) was developed, which is based on functionalizing ArMs with N-glycan targeting moieties. As a potential drug therapy, this study shows that ruthenium-bound GArM complexes could preferentially accumulate to varying cancer cell lines via glycan-based targeting for prodrug activation of the anticancer agent umbelliprenin using ring-closing metathesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available